Product Name: Hck (24-43)
Product Number: PE-01BDC80
Size: 200 µg      Price:14.00
1 mg      $US29.00
Peptide Name: Hck (24-43)

Product Use: Services as a blocking peptide for use with the Hck-ANT rabbit polyclonal antibody (Cat. No.: AB-NK271-1) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CMKSKFLQVGGNTFSKTETS

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2192.5 Da

Peptide Purity Percent after Synthesis and Purification: >50

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Hck pan-specific antibody (Cat. No.: AB-NK271-1)

Scientific Background: Hck is a protein-tyrosine kinase of the TK group and Src family. This kinase is highly expressed and widely distributed in most tested human tissues. Hck is especially expressed in certain hemopoietic cells and especially prominent in cells of myeloid lineage, particularly mature granulocytes and monocytes. It plays important roles in the regulation of the innate immune responses including leukocyte function, phagocytosis, survival and proliferation, cell adhesion and migration. It promotes the reorganization of the actin cytoskeleton and actin polymerization, as well as the formation of podosomes. Hck is also involved in the release of inflammatory molecules from the cell, and can inhibit TP73-mediated apoptosis. Aberrant activation of Hck by the BCR-Abl protein promotes cancer cell proliferation. A D399G mutation was associated with an ovarian mucinous carcinoma sample. Hck is inhibited by phosphorylation at Y522. Hck may be an oncoprotein (OP) based on its similarity to other Src family kinases that are known oncoproteins. The active form of the protein kinase normally acts to promote tumour cell proliferation. Hck has been linked with Adenosquamous carcinoma, which is a mixed lineage carcinoma made of squamous and gland cells. Hck is activated by the HIV-1 protein Nef. Its catalytic activity can be impaired, yet affinity for target peptides increased with a Y411A mutation. The Y522F mutation will constitutively activate the kinase, leading to cellular pertubations and transformation. Phosphorylation of Y522 of Hck inhibits its phosphotransferase activity. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.